Cargando…

HIV drug resistance patterns in pregnant women using next generation sequence in Mozambique

BACKGROUND: Few data on HIV resistance in pregnancy are available from Mozambique, one of the countries with the highest HIV toll worldwide. Understanding the patterns of HIV drug resistance in pregnant women might help in tailoring optimal regimens for prevention of mother to child transmission of...

Descripción completa

Detalles Bibliográficos
Autores principales: Rupérez, María, Noguera-Julian, Marc, González, Raquel, Maculuve, Sonia, Bellido, Rocío, Vala, Anifa, Rodríguez, Cristina, Sevene, Esperança, Paredes, Roger, Menéndez, Clara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5942837/
https://www.ncbi.nlm.nih.gov/pubmed/29742132
http://dx.doi.org/10.1371/journal.pone.0196451
_version_ 1783321528192991232
author Rupérez, María
Noguera-Julian, Marc
González, Raquel
Maculuve, Sonia
Bellido, Rocío
Vala, Anifa
Rodríguez, Cristina
Sevene, Esperança
Paredes, Roger
Menéndez, Clara
author_facet Rupérez, María
Noguera-Julian, Marc
González, Raquel
Maculuve, Sonia
Bellido, Rocío
Vala, Anifa
Rodríguez, Cristina
Sevene, Esperança
Paredes, Roger
Menéndez, Clara
author_sort Rupérez, María
collection PubMed
description BACKGROUND: Few data on HIV resistance in pregnancy are available from Mozambique, one of the countries with the highest HIV toll worldwide. Understanding the patterns of HIV drug resistance in pregnant women might help in tailoring optimal regimens for prevention of mother to child transmission of HIV (pMTCT) and antenatal care. OBJECTIVES: To describe the frequency and characteristics of HIV drug resistance mutations (HIVDRM) in pregnant women with virological failure at delivery, despite pMTCT or antiretroviral therapy (ART). METHODS: Samples from HIV-infected pregnant women from a rural area in southern Mozambique were analysed. Only women with HIV-1 RNA >400c/mL at delivery were included in the analysis. HIVDRM were determined using MiSeq® (detection threshold 1%) at the first antenatal care (ANC) visit and at the time of delivery. RESULTS: Ninety and 60 samples were available at the first ANC visit and delivery, respectively. At first ANC, 97% of the women had HIV-1 RNA>400c/mL, 39% had CD4+ counts <350 c/mm(3) and 30% were previously not on ART. Thirteen women (14%) had at least one HIVDRM of whom 70% were not on previous ART. Eight women (13%) had at least one HIVDRM at delivery. Out of 37 women with data available from the two time points, 8 (21%) developed at least one new HIVDRM during pMTCT or ART. Twenty seven per cent (53/191), 32% (44/138) and 100% (5/5) of the mutations that were present at enrolment, delivery and that emerged during pregnancy, respectively, were minority mutations (frequency <20%). CONCLUSIONS: Even with ultrasensitive HIV-1 genotyping, less than 20% of women with detectable viremia at delivery had HIVDRM before initiating pMTCT or ART. This suggests that factors other than pre-existing resistance, such as lack of adherence or interruptions of the ANC chain, are also relevant to explain lack of virological suppression at the time of delivery in women receiving antiretrovirals drugs during pregnancy.
format Online
Article
Text
id pubmed-5942837
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-59428372018-05-18 HIV drug resistance patterns in pregnant women using next generation sequence in Mozambique Rupérez, María Noguera-Julian, Marc González, Raquel Maculuve, Sonia Bellido, Rocío Vala, Anifa Rodríguez, Cristina Sevene, Esperança Paredes, Roger Menéndez, Clara PLoS One Research Article BACKGROUND: Few data on HIV resistance in pregnancy are available from Mozambique, one of the countries with the highest HIV toll worldwide. Understanding the patterns of HIV drug resistance in pregnant women might help in tailoring optimal regimens for prevention of mother to child transmission of HIV (pMTCT) and antenatal care. OBJECTIVES: To describe the frequency and characteristics of HIV drug resistance mutations (HIVDRM) in pregnant women with virological failure at delivery, despite pMTCT or antiretroviral therapy (ART). METHODS: Samples from HIV-infected pregnant women from a rural area in southern Mozambique were analysed. Only women with HIV-1 RNA >400c/mL at delivery were included in the analysis. HIVDRM were determined using MiSeq® (detection threshold 1%) at the first antenatal care (ANC) visit and at the time of delivery. RESULTS: Ninety and 60 samples were available at the first ANC visit and delivery, respectively. At first ANC, 97% of the women had HIV-1 RNA>400c/mL, 39% had CD4+ counts <350 c/mm(3) and 30% were previously not on ART. Thirteen women (14%) had at least one HIVDRM of whom 70% were not on previous ART. Eight women (13%) had at least one HIVDRM at delivery. Out of 37 women with data available from the two time points, 8 (21%) developed at least one new HIVDRM during pMTCT or ART. Twenty seven per cent (53/191), 32% (44/138) and 100% (5/5) of the mutations that were present at enrolment, delivery and that emerged during pregnancy, respectively, were minority mutations (frequency <20%). CONCLUSIONS: Even with ultrasensitive HIV-1 genotyping, less than 20% of women with detectable viremia at delivery had HIVDRM before initiating pMTCT or ART. This suggests that factors other than pre-existing resistance, such as lack of adherence or interruptions of the ANC chain, are also relevant to explain lack of virological suppression at the time of delivery in women receiving antiretrovirals drugs during pregnancy. Public Library of Science 2018-05-09 /pmc/articles/PMC5942837/ /pubmed/29742132 http://dx.doi.org/10.1371/journal.pone.0196451 Text en © 2018 Rupérez et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Rupérez, María
Noguera-Julian, Marc
González, Raquel
Maculuve, Sonia
Bellido, Rocío
Vala, Anifa
Rodríguez, Cristina
Sevene, Esperança
Paredes, Roger
Menéndez, Clara
HIV drug resistance patterns in pregnant women using next generation sequence in Mozambique
title HIV drug resistance patterns in pregnant women using next generation sequence in Mozambique
title_full HIV drug resistance patterns in pregnant women using next generation sequence in Mozambique
title_fullStr HIV drug resistance patterns in pregnant women using next generation sequence in Mozambique
title_full_unstemmed HIV drug resistance patterns in pregnant women using next generation sequence in Mozambique
title_short HIV drug resistance patterns in pregnant women using next generation sequence in Mozambique
title_sort hiv drug resistance patterns in pregnant women using next generation sequence in mozambique
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5942837/
https://www.ncbi.nlm.nih.gov/pubmed/29742132
http://dx.doi.org/10.1371/journal.pone.0196451
work_keys_str_mv AT ruperezmaria hivdrugresistancepatternsinpregnantwomenusingnextgenerationsequenceinmozambique
AT noguerajulianmarc hivdrugresistancepatternsinpregnantwomenusingnextgenerationsequenceinmozambique
AT gonzalezraquel hivdrugresistancepatternsinpregnantwomenusingnextgenerationsequenceinmozambique
AT maculuvesonia hivdrugresistancepatternsinpregnantwomenusingnextgenerationsequenceinmozambique
AT bellidorocio hivdrugresistancepatternsinpregnantwomenusingnextgenerationsequenceinmozambique
AT valaanifa hivdrugresistancepatternsinpregnantwomenusingnextgenerationsequenceinmozambique
AT rodriguezcristina hivdrugresistancepatternsinpregnantwomenusingnextgenerationsequenceinmozambique
AT seveneesperanca hivdrugresistancepatternsinpregnantwomenusingnextgenerationsequenceinmozambique
AT paredesroger hivdrugresistancepatternsinpregnantwomenusingnextgenerationsequenceinmozambique
AT menendezclara hivdrugresistancepatternsinpregnantwomenusingnextgenerationsequenceinmozambique